• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RITONAVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • RITONAVIR chembl:CHEMBL163 Approved

    Alternate Names:

    NSC-693184
    RITONAVIR
    ABT-538
    RITONAVIR RELATED COMPOUNDS MIXTURE
    ABBOTT-84538
    A-84538
    NORVIR
    ABT 538
    NORVIR®
    RITONAVIRUM
    N-[(1S,3S,4S)-1-BENZYL-3-HYDROXY-5-PHENYL-4-{[(1,3-THIAZOL-5-YLMETHOXY)CARBONYL]AMINO}PENTYL]-N~2~-(METHYL{[2-(1-METHYLETHYL)-1,3-THIAZOL-4-YL]METHYL}CARBAMOYL)-L-VALINAMIDE
    chemidplus:155213-67-5
    chembl:CHEMBL163
    drugbank:00503
    rxcui:85762
    pubchem.compound:392622

    Drug Info:

    (2 More Sources)

    Publications:

    Gisolf et al., 2000, Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy., J. Acquir. Immune Defic. Syndr.
    Li F et al., 2012, CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir., Drug Metab Dispos
    Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Greenblatt DJ et al., 2015, Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies., Br J Clin Pharmacol
    Tong L et al., 2007, Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro., Antimicrob Agents Chemother
    Liu X et al., 2017, Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus., Pharmacotherapy
    Tsai MS et al., 2017, Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study., J Microbiol Immunol Infect
    Bonora S et al., 2015, Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)., J Antimicrob Chemother
    Avihingsanon A et al., 2015, Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia., J Acquir Immune Defic Syndr
    Nishijima T et al., 2014, Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study., J Antimicrob Chemother
    D'Avolio A et al., 2014, Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms., J Antimicrob Chemother
    Coelho AV et al., 2013, ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients., J Clin Pharmacol
    Lubomirov R et al., 2011, Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study., J Infect Dis
    Park WB et al., 2010, Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency., Clin Infect Dis
    Ma Q et al., 2007, Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV., Pharmacogenomics
    Rodríguez-Nóvoa S et al., 2007, Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia., AIDS
    Hogg M et al., 1991, Chloride influx in human leucocytes: a triple-isotope technique for the assessment of chloride transporters., Clin Sci (Lond)
    Rodríguez Nóvoa et al., 2006, Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1., Clin. Infect. Dis.
    Haas DW et al., 2003, MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study., J Acquir Immune Defic Syndr
    da Rocha IM et al., 2015, Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort., Pharmacogenet Genomics
    Equils et al., 2004, Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation., Antimicrob. Agents Chemother.
    Arnedo M et al., 2007, Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy., Pharmacogenet Genomics
    Tarr PE et al., 2005, Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders., J Infect Dis
    Perloff et al., 2001, Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line., J Pharm Sci
    Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
    Smith CM et al., 2005, Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers., J Biochem Mol Toxicol
    Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
    Ehmann F et al., 2014, European Medicines Agency initiatives and perspectives on pharmacogenomics., Br J Clin Pharmacol
    Eagling et al., 1997, Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir., Br J Clin Pharmacol
  • RITONAVIR   APOC3

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15809899


    Sources:
    PharmGKB

  • RITONAVIR   UGT1A7

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17058217


    Sources:
    PharmGKB

  • RITONAVIR   TLR4

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15388451


    Sources:
    NCI

  • RITONAVIR   APOE

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17700364 15809899


    Sources:
    PharmGKB

  • RITONAVIR   CXCL10

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11141242


    Sources:
    NCI

  • RITONAVIR   UGT1A3

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17058217


    Sources:
    PharmGKB

  • RITONAVIR   CYP2E1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9278209


    Sources:
    NCI

  • RITONAVIR   ABCC1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11745741 23996099


    Sources:
    NCI PharmGKB

  • RITONAVIR   ABCB1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17664327 28718515 26857335 26174719 25622064 25151207 24997317 23996099 21288825 20504240 17324111 17148966 1655344 16355344 14600574


    Sources:
    DTC PharmGKB

  • RITONAVIR   IFNL3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir
    Combination therapy Ombitasvir,Paritaprevir,Ritonavir

    PMIDs:
    None found


    Sources:
    FDA

  • RITONAVIR   CYP2B6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14977870


    Sources:
    NCI

  • RITONAVIR   ABCC2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26287941


    Sources:
    PharmGKB

  • RITONAVIR   NR1I2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:

    PMIDs:
    14977870 15849716


    Sources:
    PharmGKB

  • RITONAVIR   NPSR1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RITONAVIR   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RITONAVIR   KAT2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RITONAVIR   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    21953914 21393461 9187528 25923589


    Sources:
    DTC PharmGKB

  • RITONAVIR   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24433361


    Sources:
    PharmGKB

  • RITONAVIR   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DTC: RITONAVIR

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL163 ChEMBL Drug ID

    Drug Info:

    Publications:
    Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
    Li F et al., 2012, CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir., Drug Metab Dispos
    Tong L et al., 2007, Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro., Antimicrob Agents Chemother

  • NCI: RITONAVIR

    • Version: 14-September-2017

    Alternate Names:
    C1609 NCI drug code

    Drug Info:

    Publications:
    Gisolf et al., 2000, Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy., J. Acquir. Immune Defic. Syndr.
    Equils et al., 2004, Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation., Antimicrob. Agents Chemother.
    Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.

  • PharmGKB: ritonavir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Greenblatt DJ et al., 2015, Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies., Br J Clin Pharmacol
    da Rocha IM et al., 2015, Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort., Pharmacogenet Genomics
    Arnedo M et al., 2007, Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy., Pharmacogenet Genomics

  • TTD: Ritonavir

    • Version: 2020.06.01

    Alternate Names:
    D0ZU9R TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL163

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Ritonavir

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21